Research Index

A 2026 critical review in Pharmaceutics (Mateescu et al., doi:10.3390/pharmaceutics18050625) identifies indication selection as BPC-157's structural development bottleneck: preclinical activity across gastrointestinal, musculoskeletal, neurological, and cardiovascular models means no single indication can be chosen without mechanistic rationale that the receptor-orphan status cannot supply. Each indication demands a separate IND package, a distinct administration route, and a separate bioanalytical strategy.

Yes. A 2026 Molecular Therapy study (Jati et al., PMC12776420) demonstrated that exogenous catestatin (CST) supplementation reduced pathological tau species, lowered amyloid plaque burden, and attenuated gliosis in both PS19 tauopathy and 5xFAD amyloid mouse models. The operative mechanism involves CST-mediated suppression of adrenergic–epinephrine–PKA stress signaling, which converges on CDK5 and GSK-3β to reduce tau hyperphosphorylation and amyloidogenic APP processing.

AGM-380, a cell-penetrating peptide conjugate that binds the host phosphoprotein nucleolin (NCL), protected mice from lethal influenza A virus (IAV) challenge in a September 2026 PNAS Nexus study by markedly reducing pulmonary viral replication and lung pathology. When the trifluoroacetate variant AGM-380t was co-administered with oseltamivir, 100% of animals survived — a result no monotherapy achieved.

A 2026 scoping review by Kremen et al. (UCLA Health) screened 565 studies across six widely used unapproved peptides — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu — and found the overwhelming majority of evidence is preclinical. Human data are sparse, methodologically weak, and insufficient to establish efficacy for any of the six compounds in any indication.

TRANSCEND-CKD (NCT05936151) designates iohexol plasma clearance as its primary endpoint rather than creatinine-derived eGFR. In obesity-related CKD, creatinine equations carry systematic muscle-mass biases, and retatrutide's substantial weight reduction further shifts creatinine generation. Iohexol mGFR eliminates both noise sources, enabling the trial to detect a true pharmacological signal on kidney function.

The 2026 Mateescu Pharmaceutics review (doi:10.3390/pharmaceutics18050625) and the 2025 Vasireddi systematic review in HSS Journal converge on the same verdict: BPC-157's preclinical evidence base is extensive by volume but structurally incompatible with regulatory acceptance. Non-GLP study designs, single-group concentration, absent non-human primate data, and heterogeneous outcome measures collectively disqualify the existing literature from IND-enabling status.